Literature DB >> 3094242

Histomorphometric analysis of osteoclastic bone resorption in metastatic bone disease from various primary malignomas.

H A Kulenkampff, T Dreyer, W Kersjes, G Delling.   

Abstract

The present study deals with qualitative und quantitative analysis of osteoclastic bone resorption in metastatic bone disease. 267 cases were examined histomorphologically and divided into three developmental stages. In the first 'phase of early appearance' no bone resorption takes place. The stimulation of osteoclastic resorption in the surroundings of tumour tissue is typical in the second 'phase of interaction'. Pressure atrophy, aseptic necrosis and osteolysis by the tumour cells themselves are other mechanisms of bone destruction in the last 'phase of carcinomatosis'. Because osteoclasts are exclusively responsible for the loss of bone tissue in the 'phase of interaction', this stage is suited for precise quantitative analysis of osteoclastic resorption. 24 pure osteolytic secondary bone tumours of various primary lesions were examined histomorphometrically. The numerical values were compared with each other and with standard values of healthy individuals. In contrast with normal bone tissue the fractional resorption surfaces und osteoclast indices increase in metastases. Activated osteoclasts are larger and have more nuclei. The numbers of osteoclast index and nuclei per osteoclast are significantly higher in renal than in breast carcinoma. Osteoclasts can be activated in distances of more than 500 micron from tumour tissue. The mean stimulation distance in metastasis from squamous cell carcinoma is markedly higher than in secondary bone tumours of breast carcinoma. Several osteoclast activating substances and divers mechanisms of stimulation might be responsible for different numerical values of morphometric parameters in metastases from various primary malignancies.

Entities:  

Mesh:

Year:  1986        PMID: 3094242     DOI: 10.1007/bf00710766

Source DB:  PubMed          Journal:  Virchows Arch A Pathol Anat Histopathol        ISSN: 0174-7398


  31 in total

1.  Diphosphonates.

Authors:  H Fleisch; R Felix
Journal:  Calcif Tissue Int       Date:  1979-04-17       Impact factor: 4.333

2.  Hypercalcemia and tumor-prostaglandins: the VX2 carcinoma model in the rabbit.

Authors:  E F Voelkel; A H Tashjian; R Franklin; E Wasserman; L Levine
Journal:  Metabolism       Date:  1975-08       Impact factor: 8.694

3.  Relationship of bone destruction in skeletal metastases to osteoclast activation and prostaglandins.

Authors:  C S Galasko; A Bennett
Journal:  Nature       Date:  1976-10-07       Impact factor: 49.962

4.  Prostaglandin E and hypercalcemia in breast carcinoma: only a tumor marker? A need for perspective.

Authors:  J F Caro; A Besarab; J T Flynn
Journal:  Am J Med       Date:  1979-02       Impact factor: 4.965

5.  [Simplified metacrylate embedding method for undecalcified bone sections].

Authors:  G Delling
Journal:  Beitr Pathol       Date:  1972

6.  Bone-resorbing activity in supernatants from lymphoid cell lines.

Authors:  G R Mundy; R A Luben; L G Raisz; J J Oppenheim; D N Buell
Journal:  N Engl J Med       Date:  1974-04-18       Impact factor: 91.245

7.  [Distance measurement of directed structures in the microscope and its use in the determination of surface and volume relationship in bone tissue].

Authors:  W A Merz
Journal:  Mikroskopie       Date:  1968-02

8.  The cellular basis of metastatic bone disease in patients with lung cancer.

Authors:  S F Cramer; L Fried; K J Carter
Journal:  Cancer       Date:  1981-12-15       Impact factor: 6.860

9.  Transforming growth factors produced by certain human tumor cells: polypeptides that interact with epidermal growth factor receptors.

Authors:  G J Todaro; C Fryling; J E De Larco
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

10.  Parenteral diphosphonates for treating malignant hypercalcemia.

Authors:  A Jung; C van Ouwenaller; A Chantraine; B Courvoisier
Journal:  Cancer       Date:  1981-10-15       Impact factor: 6.860

View more
  4 in total

1.  Immunolocalization of matrix metalloproteinases and their inhibitors in clinical specimens of bone metastasis from breast carcinoma.

Authors:  S Lhoták; L J Elavathil; S Vukmirović-Popović; W C Duivenvoorden; R G Tozer; G Singh
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

Review 2.  Mechanisms involved in the metastasis of cancer to bone.

Authors:  F W Orr; P Kostenuik; O H Sanchez-Sweatman; G Singh
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

3.  The role of the BMP signaling antagonist noggin in the development of prostate cancer osteolytic bone metastasis.

Authors:  Chiara Secondini; Antoinette Wetterwald; Ruth Schwaninger; George N Thalmann; Marco G Cecchini
Journal:  PLoS One       Date:  2011-01-13       Impact factor: 3.240

Review 4.  Osteoclast Fusion: Physiological Regulation of Multinucleation through Heterogeneity-Potential Implications for Drug Sensitivity.

Authors:  Kent Søe
Journal:  Int J Mol Sci       Date:  2020-10-19       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.